(12) **Translation of European patent specification**

(11) **NO/EP 2509619 B1**

(19) NO

NORWAY

(51) Int Cl.

A61K 38/13 (2006.01)
A61K 31/00 (2006.01)
A61K 31/365 (2006.01)
A61K 31/395 (2006.01)
A61K 31/436 (2006.01)
A61K 31/4427 (2006.01)
A61K 31/506 (2006.01)
A61K 38/18 (2006.01)
A61K 38/19 (2006.01)
A61K 45/06 (2006.01)
A61P 1/16 (2006.01)
A61P 9/10 (2006.01)
A61P 13/12 (2006.01)
A61P 17/00 (2006.01)
A61P 37/06 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.05.18
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.12.09
(86)	European Application Nr.	10836746.7
(86)	European Filing Date	2010.12.10
(87)	The European Application's Publication Date	2012.10.17
(30)	Priority	2009.12.11, US, 285602 P 2010.03.22, US, 316180 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Medregen, LLC, 5104 Glow Haven Way, Perry Hall, MD 21128, USA
(72)	Inventor	SUN, Zhaoli, 5104 Glow Haven Way, Perry HallMaryland 21128, USA WILLIAMS, George Melville, 826 Mill Creek Road, ArnoldMaryland 21287, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **TREATMENT METHODS UTILIZING STEM CELL MOBILIZERS AND IMMUNOSUPPRESSIVE AGENTS**

(56) References Cited:

WO-A2-2009/094456
US-A1- 2008 009 495
Bruno K. Podesser ET AL: "Comparison of Low and High Initial Tacrolimus Dosing in Primary

Heart Transplant Recipients: A Prospective European Multicenter Study", Transplantation, vol. 79, no. 1, 15 January 2005 (2005-01-15), pages 65-71, XP055110272, GB ISSN: 0041-1337, DOI: 10.1097/01.TP.0000140965.83682.D6
DAVID T. CHUNG ET AL.: "TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial", BLOOD, vol. 114, no. 22, 866, 20 November 2009 (2009-11-20), page 357,
BODART V ET AL: "Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 78, no. 8, 15 October 2009 (2009-10-15), pages 993-1000, XP026562697, ISSN: 0006-2952, DOI: 10.1016/J.BCP.2009.06.010 [retrieved on 2009-06-18]
PENTO J T: "FK-506", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 14, no. 8, 1 January 1989 (1989-01-01), pages 746-752, XP009170678, ISSN: 0377-8282
Keiichi Muramatsu ET AL: "Prolonged survival of experimental extremity allografts: A new protocol with total body irradiation, granulocyte-colony stimulation factor, and FK506", Journal of Orthopaedic Research, 1 January 2009 (2009-01-01), pages n/a-n/a, XP055110337, ISSN: 0736-0266, DOI: 10.1002/jor.21011
T. OKABAYASHI ET AL: "Mobilization of Host Stem Cells Enables Long-Term Liver Transplant Acceptance in a Strongly Rejecting Rat Strain Combination", AMERICAN JOURNAL OF TRANSPLANTATION, vol. 11, no. 10, 30 August 2011 (2011-08-30), pages 2046-2056, XP055068421, ISSN: 1600-6135, DOI: 10.1111/j.1600-6143.2011.03698.x
Tocris AMD 3465 hexahydrobromide - Certificate of Analysis Print date 14.01.2016
Burixafor Medkoo Datasheet. http://www.medkoo.com/products/7600
Kirsten E Herbert ET AL: "The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 10, no. 1, 1 December 2009 (2009-12-01), pages 113-125, XP055463000, ASHLEY, LONDON; GB ISSN: 1471-2598, DOI: 10.1517/14712590903473123
S.L. DAVIES ET AL: "Plerixafor Hydrochloride", DRUGS OF THE FUTURE, vol. 32, no. 2, 1 January 2007 (2007-01-01), page 123, XP055068423, ISSN: 0377-8282, DOI: 10.1358/dof.2007.032.02.1071897
DE CLERCQ ET AL: "Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil(TM)) and potential of other CXCR4 antagonists as stem cell mobilizers", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 128, no. 3, 1 December 2010 (2010-12-01), pages 509-518, XP027445817, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2010.08.009 [retrieved on 2010-10-26]
Margarit C; Rimola A; Gonzalez-Pinto I; Cuervas-Mons V; Edo A; Andreu H; Moreno-Gonzalez E; Calleja J L: "Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation", TRANSPLANT INTERNATIONAL., vol. 11, no. Suppl. 1, 5 June 1998 (1998-06-05), pages S260-S266, XP055110273, GB ISSN: 0934-0874, DOI: 10.1007/s001470050474
METTE M. ROSENKILDE ET AL.: "Molecular mechanism of action of Monocyclam versus Bicyclam non-peptide antagonists in the CXCR4 chemokine receptorNR-37", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 37, 14 September 2007 (2007-09-14), pages 27354-27365,

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Plerixafor (AMD3100) og Tacrolimus for anvendelse i en fremgangsmåte for behandling av en organtransplantatresipient for å fremme allograftoverlevelse og indusere allograftaksept,
hvor plerixafor (AMD3100) og Tacrolimus administreres til resipienten i en terapeutisk effektiv mengde.

2. Plerixafor (AMD3100) og Tacrolimus for anvendelse ifølge krav 1, hvor organet velges fra gruppen bestående av lever, nyre, hud, hjerte, lunge, innvoller og bukspyttkjertel.

3. Plerixafor (AMD3100) og Tacrolimus for anvendelse ifølge krav 1, hvor organet er lever.

4. Plerixafor (AMD3100) og Tacrolimus for anvendelse ifølge krav 1, hvor organet er nyre.

5. Plerixafor (AMD3100) og Tacrolimus for anvendelse ifølge krav 1, hvor organet er hud.

6. Plerixafor (AMD3100) og Tacrolimus for anvendelse i en fremgangsmåte for behandling av en vev-kompositttransplantat-resipient for å fremme allograftoverlevelse og indusere allograftaksept,
hvor plerixafor (AMD3100) og Tacrolimus administreres til resipienten i en terapeutisk effektiv mengde.

7. Plerixafor (AMD3100) og Tacrolimus for anvendelse ifølge et hvilket som helst av de foregående krav, hvor plerixafor (AMD3 100) og Tacrolimus administreres én gang annenhver dag.

8. Plerixafor (AMD3100) og Tacrolimus for anvendelse ifølge et hvilket som helst av de foregående krav, hvor plerixafor (AMD3 100) og Tacrolimus administreres én gang i måneden.